COVID-19NCT05453188
Physiotherapy for Persistent COVID-19 Disease Using Aerobic Exercise
A study testing Experimental in people with COVID-19 and Genetic Predisposition to Disease, run by Universidad Francisco de Vitoria at 1 site in Spain.
Trial summary
Aerobic exercise - Nordic walking in Persistent Covid (PC) vs. healthy controls. The main objective of this study is to analyse the genes associated with increased physical performance in patients with PC vs. Read more about this study
- Who is it for?
- Ages 30 to 60 years
- Conditions the study is for
- COVID-19, Genetic Predisposition to Disease
- What is being tested?
- Experimental
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteSpain
- Study dates
- 1 Mar 2022to 1 Jul 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Persistent symptoms of covid for more than one year.
- Age between 30 and 60 years.
- Complete vaccination schedule (one dose is sufficient, as this was considered by the Ministry for patients who have passed the disease).
- Recent basic blood test.
Who cannot join
- Presence of comorbidities of musculoskeletal origin that contraindicate the practice of the proposed exercise.
- Presence of uncontrolled cardiac or respiratory disease.
- Presence of incapacitating neurological disease that significantly interferes with the proposed exercise activity Severe anaemia or other co-morbidities that significantly interfere with the proposed exercise activity
- Diagnosis or symptoms of dysautonomia
- Presence of high rates of fatigue
- Desaturations during the exercise test that imply a need for oxygen supply for exercise
- Desaturation on exertion during exercise ≥3%.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Physiotherapy Intervention in Patients With Persistent COVID-19 Disease Using Aerobic Exercise and Association With Genetics
Aerobic exercise - Nordic walking in Persistent Covid (PC) vs. healthy controls.
The main objective of this study is to analyse the genes associated with increased physical performance in patients with PC vs. healthy controls and to measure the level of lactic acid in blood, pre and post exercise session in patients affected by PC.
Read more
Relevance: It is intended to be a tool for patients with CP who have not been hospitalised, nor have been offered outpatient rehabilitation treatment. They have not recovered their work, family, sporting or leisure functions. They have particular problems in returning to aerobic exercise.
We think that they may need to be accompanied in the recovery of their physical condition under the supervision of health professionals. Most of the studies offered to them are exploratory, not intervention. Our proposal is a 12-week intervention.
Our proposal, delves into the mechanisms that may underlie their fatigue and their problems in returning to aerobic exercise, in order to collaborate in approaching possible solutions.
Secondary objectives: To study in each of the patients with persistent covid, included in the aerobic Nordic walking programme, their DNA in order to, based on two candidate genes, analyse the role of genetic polymorphisms associated with increased VO2 max training, compared to a healthy control group.
To assess the blood lactic acid level pre and post exercise in a group of patients with persistent covid pre and post aerobic Nordic walking programme. Patients and Methods: 33 patients with CP and 33 healthy controls will follow a Nordic walking programme for 12 weeks. QIAGEN Cube automatic extractor and lactic acid meter will be used.
Read the detailed description
Design: Parallel non-randomized clinical trial. Study arms: Experimental group with Nordic walking programme (n=15) and healthy control group with the same programme (n=15).
Patients will be recruited by means of a mass mailing to their addresses in the Covid Persistente Madrid group. Participants must meet the inclusion criteria and sign the informed consent form. Patients will be asked to submit a recent basic blood test and an electrocardiogram if available.
Medical Rehabilitation Consultation for screening of patients It is assumed that the patient has already been diagnosed with longCOVID, so he/she should provide data from previous clinical history in relation to the process: time of evolution, characteristics of the syndrome, and treatments carried out.....
It is essential that the patient provides a recent blood test. Objectives To ascertain the main symptomatology presented by the patient, with relevance of signs and symptoms that cause functional limitation.
Determine the presence of comorbidities that may be a contraindication or precaution for the practice of the activity.
The estimated effect size for the main outcome measures established in this project was 0.25. Considering a power of the statistical test of 0.95, an alpha error of 0.05 and a total of five measurements in two participant groups, a minimum number of 30 participants is required, according to the G*Power software (version 3.1.7). Taking into account a loss rate of 10%, the sample size will finally consist of 30 subjects (15 subjects for each intervention group). In order to prevent possible losses, 17 subjects will be included in each group.
5.3. Spatial scope
The assessment will take place:
Consultations with the rehabilitation doctor will take place at the University Clinic of the Faculty of Health Sciences of the Rey Juan Carlos University, Madrid, Spain.
Genetic analysis: Faculty of Health Sciences. Francisco de Vitoria University. Lactic acid measurement: Outdoors, pre- and post-Nordic walking session. Since the measurement must be immediate.
The intervention will take place in the outdoor space of the Casa de Campo. Madrid, Spain.
The Nordic walking sessions will last 90 minutes (warm-up, exercise and cool down), and will be carried out for 12 weeks, with a frequency of once a week.
The instructor will start by designing routes without gradients during the first four sessions of intervention and will adapt the protocol for the following two months according to the evolution of the groups and adapted to the needs of the longCOVID patients.
Patients will be asked to record post-exercise fatigue and their heart rate and oxygen saturation will be monitored during the sessions.
DNA collection for the determination of polymorphisms will be performed on samples to optimize resources (samples will be anonymized and coded).
Samples will be obtained by swabbing and scraping of the buccal mucosa by the participant. DNA will be isolated by QIAGEN Cube automatic extractor. The DNA will be stored at -20º until use.
The genetic study will analyze single nucleotide polymorphisms (SNPs) related fundamentally to functions associated with:
- Polymorphisms of genes associated with muscle performance; ACE, ACTN3, AMPD1, CKM and MLCK
- Polymorphisms of genes for sensitivity and resistance to Covid-19 infection; ACE-2 The data will be entered into the SPSS statistical package (version 25) for analysis.
First, the Kolmogorov-Smirnov test will be used to determine whether the study variables show a normal distribution (p>0.05). Those quantitative variables that do not show a normal distribution will be analysed with non-parametric tests and their data will be expressed as median and interquartile range, while quantitative variables that show a normal distribution will be analysed with parametric tests and their data expressed as mean and standard deviation.
For variables with a normal distribution, a repeated measures analysis of variance (ANOVA) with Bonferroni a posteriori adjustment will be performed, establishing as an inter-subject factor the group parameter (experimental and control) and as an intra-subject factor each of the measurements.
The contrast of variables that do not follow a normal distribution will be carried out using the Mann-Whitney U test, comparing the differences between the groups in each measurement. Intra-group differences will be analysed using the Friedman test for k related samples. In case this test detects intra-group differences at follow-up, the Wilcoxon signed-rank test for two related samples will be used.
Between-group analysis of qualitative variables, expressed as proportions and percentages, will be performed using Pearson's chi-squared test. Intra-group differences of qualitative variables will be performed using McNemar's test for paired data.
The statistical analysis will be carried out with a confidence level of 95%, so that values with a p-value of less than 0.05 will be considered significant.
- Conditions
- COVID-19, Genetic Predisposition to Disease
- Being tested
- Experimental, Control
- Keywords
- longCOVID, Aerobic exercise, Muscle performance, Genetics
- Medical subject headings
- COVID-19, Genetic Predisposition to Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ExperimentalDevice
Also called Lactic acid, EuroQool EQ5D, SF-36, MFIS
Pre- and post-intervention measurement of quality of life, self-perceived fatigue and blood lactic acid concentration after each Nordic Walking session.
ControlGenetic
Also called ACE polimorphism, ACTN3 polymorphism, AMPD1 polymorphism, CKM polymorphism
Genetic polymorphism study by Polymerase Chain Reaction (PCR) to determine genetic profile and allele frequencies of patients with persistent COVID and association by Total Genotype Score (TGS) with fatigue status.
| Study group | Role | What they receive |
|---|---|---|
| LongCOVID | Experimental | Patients who have had COVID-19 and have been diagnosed with longCOVID or persistent COVID Receives: Device: Experimental; Genetic: Control |
| Control | Active comparator | Patients who have had COVID-19, but have not been diagnosed with longCOVID or persistent COVID Receives: Device: Experimental; Genetic: Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Lactic acid concentration
A small blood sample (0.3 microlitres) will be taken from the participant, by puncturing the index finger of the hand, to perform a blood lactate analysis. Pre-exercise and immediately after the physical activity
Measured: Changes from baseline and at the end of procedure (12 weeks)
EuroQoL Quality of Life Scale (EQ5D)
The EuroQoL Quality of Life Scale (EQ5D) is an instrument which evaluates the generic quality of life developed in Europe and widely used. The EQ-5D descriptive system is a preference-based HRQL measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Descriptive data from the 5 dimensions of Part I can be used to generate a health-related quality of life profile for the subject. Part II is scored from 0 (worst health state imaginable) to 100 (best health state imaginable). The score from Part II can be used to track changes in health, on an individual or group level, over time
Measured: Changes from baseline and at the end of procedure (12 weeks)
36-Item Short Form Survey (SF-36)
The 36-Item Short Form Survey (SF-36) is a measure of health status and an abbreviated variant of it, the SF-6D, is commonly used in health as a variable in the quality-adjusted life year calculation to determine the cost-effectiveness of a health treatment. SF-36 scale is directly transformed into a 0-100 on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Measured: Changes from baseline and at the end of procedure (12 weeks)
Modified Fatigue Impact Scale (MFIS)
The Modified Fatigue Impact Scale (MFIS) is a modified form of the Fatigue Impact Scale based on items derived from interviews with MS patients concerning how fatigue impacts their lives.The total score of the MFIS ranges from 0 to 84. The ranges of scores for each subscale are as follows: physical, 0 to 36; cognitive, 0 to 40; and psychosocial, 0 to 8. A higher score means fatigue is more significantly affecting patient´s life.
Measured: Changes from baseline and at the end of procedure (12 weeks)
Secondary outcomes (8)
Genotype frequency of ACE polymorphism
Samples shall be obtained by swabbing and scraping of the buccal mucosa by the participant. The I/D polymorphism study (rs4340) of angiotensine-converting enzime (ACE) will be used to study blood pressure related to muscle performance.
Measured: Baseline
Genotype frequency of ACTN3 polymorphism
Samples shall be obtained by swabbing and scraping of the buccal mucosa by the participant. The study of the c.1729C>T polymorphism (rs1815739) of alpha-actinine3 (ACTN3) will be used to study the composition of muscle fibres and their relationship with muscle performance.
Measured: Baseline
Genotype frequency of AMPD1 polymorphism
Samples shall be obtained by swabbing and scraping of the buccal mucosa by the participant. The study of the c.34C>T polymorphism (rs17602729) of adenosine monophosphate deaminase 1 (AMPD1) will be used to study muscle metabolism and energy efficiency with its relation to muscle performance.
Measured: Baseline
Genotype frequency of CKM polymorphism
Samples shall be obtained by swabbing and scraping of the buccal mucosa by the participant. The study of the c.*800A>G polymorphism (rs8111989) of muscle-specific creatine kinase (CKM) will be used to study muscle damage during exercise with its relationship to muscle performance.
Measured: Baseline
Genotype frequency of MLCK c.49C>T polymorphism
Samples shall be obtained by swabbing and scraping of the buccal mucosa by the participant. The study of the c.49C>T polymorphism (rs2700352) of myosin-light chain kinase (MLCK) will be used to study muscle damage and loss of strenght during exercise with its relationship to muscle performance.
Measured: Baseline
Genotype frequency of MLCK c.37885C>A polymorphism
Samples shall be obtained by swabbing and scraping of the buccal mucosa by the participant. The study of the c.37885C>A polymorphism (rs28497577) of myosin-light chain kinase (MLCK) will be used to study muscle damage and loss of strenght during exercise with its relationship to muscle performance.
Measured: Baseline
Genotype frequency of ACE2 rs2106806 polymorphism
Samples will be obtained by swabbing and scraping the buccal mucosa by the participant. The study of the angiotensin-converting enzyme 2 (ACE2) rs2106806 polymorphism will be used to study the susceptibility of patients for SARS-CoV-2 infection.
Measured: Baseline
Genotype frequency of ACE2 rs6629110 polymorphism
Samples will be obtained by swabbing and scraping the buccal mucosa by the participant. The study of the angiotensin-converting enzyme 2 (ACE2) rs6629110 polymorphism will be used to study the susceptibility of patients for SARS-CoV-2 infection.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jul 2022
- Study start1 Mar 2022
- Primary completion1 Jul 2022
- Study completion1 Jul 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universidad Francisco de Vitoria
- Sponsor type
- University, hospital or other
- Collaborators
- Universidad Rey Juan Carlos
- Responsible party
- Sponsor
- Investigators
- David Varillas Delgado, PhD, Principal investigator, Universidad Francisco de Vitoria, crta Pozuelo-Majadahonda km 1.800 PC 28223, Madrid, Spain
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05453188
- Sponsor's protocol ID
- URJCLactate
- Status last verified
- Jul 2022
- First submitted
- 11 Jul 2022
- Last updated
- 14 Aug 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Physiotherapy Intervention in Patients With Persistent COVID-19 Disease Using Aerobic Exercise and Association With Genetics
- ClinicalTrials.gov ID
- NCT05453188
- Acronym / sponsor ID
- URJCLactate
- Conditions
- COVID-19, Genetic Predisposition to Disease
- Keywords
- longCOVID, Aerobic exercise, Muscle performance, Genetics
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Universidad Francisco de VitoriaUniversity, hospital or other
- Collaborators
- Universidad Rey Juan Carlos
- Study start
- 1 Mar 2022 (actual)
- Primary completion
- 1 Jul 2022 (actual)
- Study completion
- 1 Jul 2022 (actual)
- First posted
- 12 Jul 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Aerobic exercise - Nordic walking in Persistent Covid (PC) vs. healthy controls.
The main objective of this study is to analyse the genes associated with increased physical performance in patients with PC vs. healthy controls and to measure the level of lactic acid in blood, pre and post exercise session in patients affected by PC.
Relevance: It is intended to be a tool for patients with CP who have not been hospitalised, nor have been offered outpatient rehabilitation treatment. They have not recovered their work, family, sporting or leisure functions. They have particular problems in returning to aerobic exercise.
We think that they may need to be accompanied in the recovery of their physical condition under the supervision of health professionals. Most of the studies offered to them are exploratory, not intervention. Our proposal is a 12-week intervention.
Our proposal, delves into the mechanisms that may underlie their fatigue and their problems in returning to aerobic exercise, in order to collaborate in approaching possible solutions.
Secondary objectives: To study in each of the patients with persistent covid, included in the aerobic Nordic walking programme, their DNA in order to, based on two candidate genes, analyse the role of genetic polymorphisms associated with increased VO2 max training, compared to a healthy control group.
To assess the blood lactic acid level pre and post exercise in a group of patients with persistent covid pre and post aerobic Nordic walking programme. Patients and Methods: 33 patients with CP and 33 healthy controls will follow a Nordic walking programme for 12 weeks. QIAGEN Cube automatic extractor and lactic acid meter will be used.
Detailed description
Design: Parallel non-randomized clinical trial. Study arms: Experimental group with Nordic walking programme (n=15) and healthy control group with the same programme (n=15).
Patients will be recruited by means of a mass mailing to their addresses in the Covid Persistente Madrid group. Participants must meet the inclusion criteria and sign the informed consent form. Patients will be asked to submit a recent basic blood test and an electrocardiogram if available.
Medical Rehabilitation Consultation for screening of patients It is assumed that the patient has already been diagnosed with longCOVID, so he/she should provide data from previous clinical history in relation to the process: time of evolution, characteristics of the syndrome, and treatments carried out.....
It is essential that the patient provides a recent blood test. Objectives To ascertain the main symptomatology presented by the patient, with relevance of signs and symptoms that cause functional limitation.
Determine the presence of comorbidities that may be a contraindication or precaution for the practice of the activity.
The estimated effect size for the main outcome measures established in this project was 0.25. Considering a power of the statistical test of 0.95, an alpha error of 0.05 and a total of five measurements in two participant groups, a minimum number of 30 participants is required, according to the G*Power software (version 3.1.7). Taking into account a loss rate of 10%, the sample size will finally consist of 30 subjects (15 subjects for each intervention group). In order to prevent possible losses, 17 subjects will be included in each group.
5.3. Spatial scope
The assessment will take place:
Consultations with the rehabilitation doctor will take place at the University Clinic of the Faculty of Health Sciences of the Rey Juan Carlos University, Madrid, Spain.
Genetic analysis: Faculty of Health Sciences. Francisco de Vitoria University. Lactic acid measurement: Outdoors, pre- and post-Nordic walking session. Since the measurement must be immediate.
The intervention will take place in the outdoor space of the Casa de Campo. Madrid, Spain.
The Nordic walking sessions will last 90 minutes (warm-up, exercise and cool down), and will be carried out for 12 weeks, with a frequency of once a week.
The instructor will start by designing routes without gradients during the first four sessions of intervention and will adapt the protocol for the following two months according to the evolution of the groups and adapted to the needs of the longCOVID patients.
Patients will be asked to record post-exercise fatigue and their heart rate and oxygen saturation will be monitored during the sessions.
DNA collection for the determination of polymorphisms will be performed on samples to optimize resources (samples will be anonymized and coded).
Samples will be obtained by swabbing and scraping of the buccal mucosa by the participant. DNA will be isolated by QIAGEN Cube automatic extractor. The DNA will be stored at -20º until use.
The genetic study will analyze single nucleotide polymorphisms (SNPs) related fundamentally to functions associated with:
- Polymorphisms of genes associated with muscle performance; ACE, ACTN3, AMPD1, CKM and MLCK
- Polymorphisms of genes for sensitivity and resistance to Covid-19 infection; ACE-2 The data will be entered into the SPSS statistical package (version 25) for analysis.
First, the Kolmogorov-Smirnov test will be used to determine whether the study variables show a normal distribution (p>0.05). Those quantitative variables that do not show a normal distribution will be analysed with non-parametric tests and their data will be expressed as median and interquartile range, while quantitative variables that show a normal distribution will be analysed with parametric tests and their data expressed as mean and standard deviation.
For variables with a normal distribution, a repeated measures analysis of variance (ANOVA) with Bonferroni a posteriori adjustment will be performed, establishing as an inter-subject factor the group parameter (experimental and control) and as an intra-subject factor each of the measurements.
The contrast of variables that do not follow a normal distribution will be carried out using the Mann-Whitney U test, comparing the differences between the groups in each measurement. Intra-group differences will be analysed using the Friedman test for k related samples. In case this test detects intra-group differences at follow-up, the Wilcoxon signed-rank test for two related samples will be used.
Between-group analysis of qualitative variables, expressed as proportions and percentages, will be performed using Pearson's chi-squared test. Intra-group differences of qualitative variables will be performed using McNemar's test for paired data.
The statistical analysis will be carried out with a confidence level of 95%, so that values with a p-value of less than 0.05 will be considered significant.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| LongCOVID | Experimental | Device: Experimental, Genetic: ControlPatients who have had COVID-19 and have been diagnosed with longCOVID or persistent COVID |
| Control | Active comparator | Device: Experimental, Genetic: ControlPatients who have had COVID-19, but have not been diagnosed with longCOVID or persistent COVID |
Who may qualify
- Ages
- 30 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Persistent symptoms of covid for more than one year.
- Age between 30 and 60 years.
- Complete vaccination schedule (one dose is sufficient, as this was considered by the Ministry for patients who have passed the disease).
- Recent basic blood test.
Key exclusion criteria (7 listed)
- Presence of comorbidities of musculoskeletal origin that contraindicate the practice of the proposed exercise.
- Presence of uncontrolled cardiac or respiratory disease.
- Presence of incapacitating neurological disease that significantly interferes with the proposed exercise activity Severe anaemia or other co-morbidities that significantly interfere with the proposed exercise activity
- Diagnosis or symptoms of dysautonomia
- Presence of high rates of fatigue
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ExperimentalAlso: Lactic acid, EuroQool EQ5D, SF-36, MFISPre- and post-intervention measurement of quality of life, self-perceived fatigue and blood lactic acid concentration after each Nordic Walking session. | Device | Control, LongCOVID |
| ControlAlso: ACE polimorphism, ACTN3 polymorphism, AMPD1 polymorphism, CKM polymorphismGenetic polymorphism study by Polymerase Chain Reaction (PCR) to determine genetic profile and allele frequencies of patients with persistent COVID and association by Total Genotype Score (TGS) with fatigue status. | Genetic | Control, LongCOVID |
Primary outcome
Lactic acid concentration
Time frame: Changes from baseline and at the end of procedure (12 weeks)
A small blood sample (0.3 microlitres) will be taken from the participant, by puncturing the index finger of the hand, to perform a blood lactate analysis. Pre-exercise and immediately after the physical activity
EuroQoL Quality of Life Scale (EQ5D)
Time frame: Changes from baseline and at the end of procedure (12 weeks)
The EuroQoL Quality of Life Scale (EQ5D) is an instrument which evaluates the generic quality of life developed in Europe and widely used. The EQ-5D descriptive system is a preference-based HRQL measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Descriptive data from the 5 dimensions of Part I can be used to generate a health-related quality of life profile for the subject. Part II is scored from 0 (worst health state imaginable) to 100 (best health state imaginable). The score from Part II can be used to track changes in health, on an individual or group level, over time
36-Item Short Form Survey (SF-36)
Time frame: Changes from baseline and at the end of procedure (12 weeks)
The 36-Item Short Form Survey (SF-36) is a measure of health status and an abbreviated variant of it, the SF-6D, is commonly used in health as a variable in the quality-adjusted life year calculation to determine the cost-effectiveness of a health treatment. SF-36 scale is directly transformed into a 0-100 on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Modified Fatigue Impact Scale (MFIS)
Time frame: Changes from baseline and at the end of procedure (12 weeks)
The Modified Fatigue Impact Scale (MFIS) is a modified form of the Fatigue Impact Scale based on items derived from interviews with MS patients concerning how fatigue impacts their lives.The total score of the MFIS ranges from 0 to 84. The ranges of scores for each subscale are as follows: physical, 0 to 36; cognitive, 0 to 40; and psychosocial, 0 to 8. A higher score means fatigue is more significantly affecting patient´s life.
8 secondary outcomes
Genotype frequency of ACE polymorphism
Time frame: Baseline
Genotype frequency of ACTN3 polymorphism
Time frame: Baseline
Genotype frequency of AMPD1 polymorphism
Time frame: Baseline
Genotype frequency of CKM polymorphism
Time frame: Baseline
Genotype frequency of MLCK c.49C>T polymorphism
Time frame: Baseline
Genotype frequency of MLCK c.37885C>A polymorphism
Time frame: Baseline
Genotype frequency of ACE2 rs2106806 polymorphism
Time frame: Baseline
Genotype frequency of ACE2 rs6629110 polymorphism
Time frame: Baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2023.
Related trials for COVID-19
RecruitingObservational study
Viral Infections in Healthy and Immunocompromised Hosts
Anogenital Herpes, COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
RecruitingPhase 4
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations
SARS-CoV-2
Not yet recruitingPhase 2
Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome
Long COVID, COVID-19 (SARS-CoV-2 Infection)
Active, not recruiting
Motivational Interviewing Intervention for Families With Overweight and Obesity
Obesity & Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David Varillas Delgado, PhD principal investigator
Universidad Francisco de Vitoria, crta Pozuelo-Majadahonda km 1.800 PC 28223, Madrid, Spain
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Experimental in people with COVID-19 and Genetic Predisposition to Disease, run by Universidad Francisco de Vitoria at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Lactic acid concentration (time frame: Changes from baseline and at the end of procedure (12 weeks)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2023.